Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

Dr. Lee will oversee the clinical development of Lycia’s lead programs, LCA-0061 for IgE-mediated diseases and LCA-0321 for Graves’ disease SOUTH SAN FRANCISCO, CA, February 11, 2025 – Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, […] The post Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline appeared first on Lycia Therapeutics .